SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending due to a newly announced $14 billion deal with Meta to provide computing power for AI infrastructure, fueling discussions about the increasing demand for AI capabilities. Community members are highlighting the significance of this deal, CoreWeave's partnership with Nvidia, and potential future partnerships. Some traders are monitoring price action, while others are focused on long-term bullish prospects in the AI sector.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending after announcing multiple AI partnerships with tech giants like NVIDIA, OpenAI, Google (Gemini), and Snowflake, sparking excitement about its leadership in agentic AI. The community is buzzing about a potential short squeeze given the high short interest and potential for a run similar to $CRWV or $PLTR, while also debating the impact of the CEO's ongoing stock sales and comparing PATH to competitors like $PLTR.

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed ($WOLF) is trending due to its emergence from Chapter 11 bankruptcy and a complex stock restructuring, which has led to significant price volatility and confusion among investors. Community discussions revolve around the impact of share cancellations, reverse stock splits, and potential short squeezes, with many users expressing frustration over diluted holdings while others speculate on future upside. The restructuring aims to reduce debt and position the company for growth in the silicon carbide market, but the immediate effects on shareholders are heavily debated.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as CoreWeave ($CRWV) secured a massive deal to provide computing power for its AI infrastructure, sparking excitement among bulls.  The community is discussing the deal's implications for the AI race and META's potential growth, while analysts are also weighing in with positive ratings. The news highlights the significant investments being made in AI and META's continued focus on the sector.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as shareholders discuss the implications of Sanofi's continued use of its Matrix-M adjuvant. Community members are speculating about a potential acquisition by Sanofi, while also expressing concerns about leadership and the lack of a CIC partnership, leading to calls for greater transparency and action to improve shareholder value.

Draganfly, Inc. engages in the manufacture and sale of commercial unmanned aerial vehicle systems and software serving the public safety, agriculture, industrial inspections, security, mapping, and surveying markets. Its products include quad-copters, fixed wing aircrafts, ground based robots, hand held controllers, and software used for tracking, live streaming, and data collection. The firm also offers custom engineering, training, simulation consulting, as well as data and flight training services. The company was founded by Zenon Dragan and Christine Dragan in 1998 and is headquartered in Saskatoon, Canada.

Draganfly Inc

Draganfly is trending following news of the U.S. Army selecting the company to supply drone systems and support manufacturing at overseas military facilities, which the community views as a major long-term opportunity. Discussions also revolve around the potential size of the Army contract and the possibility of a short squeeze, while some traders caution about potential offerings. Bullish sentiment is high, with some anticipating substantial gains for the drone stock.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending due to recent data highlighting the potential of oral blarcamesine in treating Alzheimer's, particularly for APOE4 carriers excluded from other trials. The community is discussing the significance of the new data and its implications for regulatory approval, with some expressing frustration over the stock's perceived undervaluation and market manipulation. Despite some skepticism, there's optimism surrounding the drug's potential as a disease-modifying treatment with a favorable safety profile.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharma ($AUPH) is trending due to a controversy sparked by a LinkedIn post from an FDA official questioning the clinical benefit and safety of its drug, Lupkynis, leading to a significant stock selloff. The community is actively discussing potential market manipulation, possible motivations behind the post given past relationships, and the company's response. Some investors are calling for legal action and an investigation into the matter, while others view this as a buying opportunity, noting the deletion of the post and strong underlying fundamentals.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending due to a new agreement with Corning for ceramic separator development and commercialization, sparking discussions about potential mass production and OEM partnerships. The community is buzzing with speculation about which major companies might be next, with some eyeing Tesla and Panasonic. However, some traders are skeptical of the hype, citing a lack of revenue and commercialized products.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific is trending due to ongoing discussions about its proposed merger with CoreWeave, with investors weighing the deal's value and potential renegotiation, especially given CoreWeave's stock performance and lockup expiration. The community is focused on the upcoming vote and whether the current terms adequately compensate CORZ shareholders amid the rapidly evolving AI landscape and increasing demand for data centers. Bullish sentiment is fueled by institutional investment and potential for re-rating as an AI play.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Theratechnologies Inc. (THTX) traded 46% higher on Friday noon after Michigan-based Future Pak LLC announced that it has submitted a fresh proposal to acquire all outstanding shares of the company’s common stock.Future Pak is a privately held contract manufacturer and packager of pharmaceutical and nutraceutical products.The company’s new proposal offers a cash consideration of $3.51 to $4.50 per share, implying a premium of 164% to 238% on Theratechnologies’ closing price of $1.33 on Thursday.The proposal represents an enterprise value of up to $255 million, including $205 million in cash and up to $50 million in contingent value right payments.Future Pak said the offer remains open for consideration by Theratechnologies and its Board. The contract manufacturer highlighted that it has submitted two formal proposals to Theratechnologies since January, including the recent proposal, but received minimal engagement from the company.Future Pak Chief Growth Officer Nirav Patel said the firm believes the proposal provides a “significant upside” and a “solid foundation” for constructive dialogue.The company added that the proposed transaction would not be subject to a financing contingency and has the full support of its strategic financial partner, Colbeck Capital Management.On Stocktwits, retail sentiment around Theratechnologies rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume jumped from ‘extremely low’ to ‘extremely high.’<figure class="image"><img style="aspect-ratio:1292/308;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_11_at_12_39_25_PM_png_ebb8e8c704.webp" alt="THTX's Sentiment Meter and Message Volume as of 12:40 p.m. ET on April 11, 2025 | Source: Stocktwits" width="1292" height="308"><figcaption>THTX's Sentiment Meter and Message Volume as of 12:40 p.m. ET on April 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the proposal shows how undervalued the stock is.<stembedurl>https://stocktwits.com/s586576/message/611379645</stembedurl>Another, however, expressed surprise at why the Board did not accept the proposal despite its significant premium.<stembedurl>https://stocktwits.com/RSVinLA/message/611384955</stembedurl><a href="https://stocktwits.com/symbol/THTX">THTX stock</a> has gained nearly 6% in 2025 and about 31% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/jpmorgans-jamie-dimon-sees-sp-500-earnings-estimates-contracting-due-to-trump-tariffs/chfroASRb9j">Jamie Dimon Sees S&amp;P 500 Earnings Estimates Contract As Trump Tariffs Force Companies To Withdraw Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Theratechnologies Stock Soars On Acquisition Bid From Future Pak: Retail’s Overjoyed

Future Pak’s proposal offers a cash consideration of $3.51 to $4.50 per share, implying a premium of 164% to 238% on Theratechnologies’ closing price of $1.33 on Thursday.

Equity

Shares of Theratechnologies Inc. (THTX) tumbled 16% on Wednesday after the company’s first-quarter <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.theratech.com/news-releases/news-release-details/theratechnologies-reports-financial-results-first-quarter-2025">earnings</a> fell below Wall Street estimates.Theratechnologies reported a revenue of $19.05 million, marking a growth of 17.2% from the corresponding period last year, but below an analyst estimate of $20.43 million, according to FinChat data.Revenue from the sales of Egrifta SV, used to treat HIV-related excess visceral abdominal fat, jumped by nearly 45% due to higher unit sales and higher selling price.Unit sales rose as the company rebuilt its distributor and pharmacy inventories following a supply disruption resulting in a one-time loss of six to seven weeks of sales.CEO Paul Lévesque said that while the number is mainly related to reloading the pipeline following an end to the temporary supply disruption, the fundamentals of the business and specifically demand for Egrifta SV remains very strong.He added that the HIV portfolio led by the Egrifta franchise will continue to remain an “engine of growth” for years.The company reported positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $2.3 million, compared to a loss of $247,000 in the same quarter of 2024, but below an estimated $3.93 million.For the fiscal year 2025, the company estimates revenue in the range of $80 million to $83 million and adjusted EBITDA to be between $10 and $12 million, below an estimated $21.16 million.On Stocktwits, retail sentiment around Theratechnologies fell from ‘neutral’ to ‘bearish’ territory, coupled with ‘extremely low’ message volume over the past 24 hours.<figure class="image"><img style="aspect-ratio:651/148;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_09_at_12_04_56_PM_png_e8d5a9a3b7.webp" alt="THTX's Sentiment Meter and Message Volume as of 12:00 p.m. ET on April 9, 2025 | Source: Stocktwits" width="651" height="148"><figcaption>THTX's Sentiment Meter and Message Volume as of 12:00 p.m. ET on April 9, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/THTX">THTX shares</a> have been down nearly 30% this year and over 16% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/bernstein-downgrades-ford-motor-co-cuts-price-target/chfn9uoRbB2">Ford Stock In Spotlight After Bernstein Downgrade, Price Target Cut: Retail Stays Pessimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Theratechnologies Stock Plummets On Disappointing Q1 Earnings, Full Year Forecast: Retail Sentiment Sours

For the fiscal year 2025, the company estimates revenue in the range of $80 million to $83 million and adjusted EBITDA to be between $10 and $12 million. 

Examining the Future: Theratechnologies's Earnings Outlook

Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays

Theratechnologies anticipates a temporary supply disruption of Egrifta SV in 2025 due to an FDA-linked manufacturer shutdown, but the company is working to minimize the impact while adjusting revenue...

HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soars

Theratechnologies reports Q2 2024 sales of $22.02 million, a 25.5% YoY increase, driven by strong demand for EGRIFTA SV. Net income reached $1 million with an adjusted EBITDA of $5.5 million. The...

Theratechnologies Appoints Elina Tea to its Board of Directors

MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ( Theratechnologies or the Company ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...

Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update

MONTREAL, April 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ( Theratechnologies or the Company ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...

Theratechnologies Inc. (NASDAQ:THTX) Short Interest Down 35.7% in March

Theratechnologies Inc. (NASDAQ:THTX - Get Free Report) was the recipient of a large drop in short interest in March. As of March 15th, there was short interest totalling 17,100 shares, a drop of...

Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology  Platform

Study to assess new camptothecin-peptide conjugates for the treatment of sortilin-positive colorectal cancers Separate data to highlight activity of sudocetaxel zendusortide (TH1902) to trigger the...

Theratechnologies Appoints Jordan Zwick to its Board of Directors

MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ( Theratechnologies or the Company ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...

Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montréal, Canada.

Theratechnologies Inc.

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$3.39
Prev Close	$3.39
Open	$3.36
Dividend Yield	N/A
50-Day Moving Average	$3.24
Beta	0.89
Avg. Volume	340,987.38
PE Ratio	-17.18

52-Week High	$3.40
52-Week Low	$1.12
Market Capitalization	$155.87M
EPS (Annual)	-$0.1683
Price to Book	-5.58
Revenue Per Employee	$817,771.43
Enterprise Value/EBITDA	N/A

THTX
Theratechnologies Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest THTX News

THTX Theratechnologies Inc.